113 results
Page 2 of 6
8-K
EX-99.1
whx 58d0iy44yvr6
26 Mar 24
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
4:05pm
8-K
EX-99.1
mdak9n9z 851omaqvc9v
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
EX-99.1
qquatz5iv6ioooc
8 Jan 24
Regulation FD Disclosure
4:09pm
8-K
EX-99.1
0nh ycspy
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
8-K
EX-1.1
qawzg qtqhnyg0
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
424B5
4znc1wa
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
nz1uuhjx380ylrcq6
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.2
rzkwdcapqjd 9x950
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.1
t45ne91v6
13 Nov 23
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
93j99
24 Oct 23
Annexon Receives Prime Designation from the Ema for ANX007 for the Treatment of Geographic Atrophy
4:30pm
8-K
EX-99.1
bz3a33qaix
11 Oct 23
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal
4:44pm
8-K
EX-99.1
4cdo2b v5hl2602rv7
7 Aug 23
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
4:12pm
8-K
EX-99.2
6rbbdu
31 Jul 23
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
4:30pm